Patent
Antitrust
Second Circuit
In re DDAVP Direct Purchaser Antitrust Litigation
2006-5525
USDC SD New York
Was the district court correct to dismiss a class action for lack of standing where plaintiffs alleged inter alia Sherman Act § 2 monopolization, Walker Process fraud in procuring a patent on desmopressin acetate (DDAVP) tablets, improprer listing of the DDAVP patent in the United States Food and Drug Administration’s Orange Book, and sham infringement litigation against generic competitors to compel payment of monopolistic drug prices?